Targeted therapies such as trastuzumab (Herceptin) and pertuzumab (Perjeta) have shown significant efficacy in HER2-positive breast cancer patients, with improvements in both PFS and OS [202]. The gene discussed is ERBB2; the disease is breast carcinoma.